Eupraxia Pharmaceuticals Advances Diffusphere Platform Toward Phase 3 EoE Trial Following DDW Data

As Eupraxia Pharmaceuticals prepares to initiate a Phase 3 trial in Eosinophilic Esophagitis, formulation and fill-finish teams should begin mapping the specialized manufacturing requirements that the company's Diffusphere controlled-release platform will demand at commercial scale. The clinical-stage company reported Q2 2026 financial results on August 11, disclosing interim Phase 1b/2a RESOLVE trial data and a series of executive appointments that signal an accelerating late-stage development timeline.

Data presented at Digestive Disease Week (DDW) in May showed that EP-104GI, an injectable corticosteroid formulated on the Diffusphere platform, produced measurable improvement in both tissue inflammation and fibrosis sub-scores on the EoEHSS histologic scale across the highest dose cohorts. EREFS endoscopic scoring further demonstrated a dose-injection relationship, with greater cumulative injections correlating with broader esophageal improvement. Nine-month follow-up from Cohort 9 (n=3) confirmed clinical remission in symptoms in 66% of patients at week 36, a level first achieved at week 8 and sustained through the observation window.

The Phase 2b trial is underway, with interim data targeting key clinical and histologic endpoints expected in Q4 2026. A subsequent Phase 3 initiation and expansion of EP-104GI into a broader GI indication portfolio are planned for 2027. For technical operations and QA leads, the compressed timeline between interim readout and Phase 3 entry compresses the window for process validation and any formulation bridging studies required under 21 CFR Part 211 and ICH Q10 lifecycle management principles.

Eupraxia also restructured its technical leadership this quarter. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, while Dr. Alex Therien assumed the EVP, Research and Development role. Three board appointments, Robert Bazemore, Amy Pott, and Dr. Helen Thackray, added late-stage development and commercialization depth. The company also announced a geographic transition from Victoria to a two-hub operational model, a structural change with direct implications for quality system continuity and site transfer documentation requirements.

The Q4 2026 interim data release from the Phase 2b trial will serve as the primary decision gate for Phase 3 entry and will define the formulation and sterility assurance specifications that contract manufacturers and internal fill-finish operations will need to qualify ahead of pivotal supply commitments.

Source: Eupraxia Pharmaceuticals Inc. via GlobeNewswire, August 11, 2026.